Profile
Sector:
HealthcareCountry:
United StatesIPO:
13 November 2018Website:
http://www.etonpharma.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 10 min agoDividend
Analysts recommendations
Institutional Ownership
ETON Latest News
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a pharmaceutical company specializing in rare disease treatments, will have its CEO Sean Brynjelsen and CFO James Gruber present at the Citizens JMP Life Sciences Conference in New York.
Eton Pharmaceuticals, Inc. (ETON) Q4 2023 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (ETON) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.04 per share a year ago.
DEER PARK, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter and full year 2023 financial results on Thursday, March 14, 2024. Management will host a conference call and live audio webcast to discuss these results at 4:30 p.m. ET (3:30 p.m. CT).
Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Officer James Gruber - Chief Financial Officer Conference Call Participants Raghuram Selvaraju - H.C. Wainwright Operator Good afternoon, and welcome to the Eton Pharmaceuticals Third Quarter 2023 Financial Results Conference Call.
DEER PARK, Ill., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients suffering from rare diseases, today announced that it will report third quarter 2023 financial results on Thursday, November 9, 2023. Management will host a conference call and live audio webcast to discuss these results at 4:30 p.m. ET (3:30 p.m. CT).
Eton Pharmaceuticals, Inc. (ETON) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Eton Pharmaceuticals, Inc. is a small specialty pharmaceutical company whose main product ALKINDI SPRINKLE is gaining market share. The stock has doubled since reporting second quarter results one month ago. Can the rally continue? An investment analysis follows in the paragraphs below.
DEER PARK, Ill., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that Sean Brynjelsen, Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference in New York City as follows:
Eton Pharmaceuticals, Inc. (ETON) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
What type of business is Eton Pharmaceuticals?
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
What sector is Eton Pharmaceuticals in?
Eton Pharmaceuticals is in the Healthcare sector
What industry is Eton Pharmaceuticals in?
Eton Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry
What country is Eton Pharmaceuticals from?
Eton Pharmaceuticals is headquartered in United States
When did Eton Pharmaceuticals go public?
Eton Pharmaceuticals initial public offering (IPO) was on 13 November 2018
What is Eton Pharmaceuticals website?
https://www.etonpharma.com
Is Eton Pharmaceuticals in the S&P 500?
No, Eton Pharmaceuticals is not included in the S&P 500 index
Is Eton Pharmaceuticals in the NASDAQ 100?
No, Eton Pharmaceuticals is not included in the NASDAQ 100 index
Is Eton Pharmaceuticals in the Dow Jones?
No, Eton Pharmaceuticals is not included in the Dow Jones index
When does Eton Pharmaceuticals report earnings?
The next expected earnings date for Eton Pharmaceuticals is 09 August 2024